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While the slope of decline in FEV1 has traditionally been calculated from the post- rather than
the pre-bronchodilator measurement in COPD interventional trials, it is not clear whether and
to what extent these two slopes differ in symptomatic patients with COPD. Therefore, we used
data from the 4-year UPLIFT trial of tiotropium 18 mcg QD vs. placebo to compare annual rates
of change in pre- vs. post-bronchodilator FEV1 in 5041 patients with moderate to very severe
COPD (mean FEV1 48% pred) in whom the post-bronchodilator FEV1 was measured after 4 inha-
lations of two different classes of short-acting inhaled bronchodilators at baseline and 1 month
and every 6 months post-randomization over 4 years. Linear mixed effects models were used to
estimate annual rates of decline in FEV1 and FVC pre- and post-bronchodilator in each treat-
ment group separately, after adjusting for height, gender, smoking status, baseline % pre-
dicted FEV1 or FVC, and baseline acute % improvement in lung function. The slopes of the
post-bronchodilator FEV1 and FVC were significantly steeper than the pre-bronchodilator
slopes regardless of treatment arm (p < 0.001), while the estimated variances of the slopes
were similar. Post-bronchodilator increases in FEV1 and FVC diminished progressively and
significantly (p < 0.0001) over the 4-year trial, suggesting a possible explanation for the signif-
icant differences between the pre- and post-bronchodilator slopes. While the reasons for these
differences are not completely clear, they are important to consider when assessing treatment
effects on rates of decline in FEV1 and FVC.
ª 2013 Elsevier Ltd. All rights reserved.0 825 3163; fax: þ1 310 206 5088.
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Pre- vs. post-bronchodilator slopes of FEV1 change 1905Introduction treatment groups was performed using t-tests for normally-For nearly 50 years the rate of progression of COPD has been
definedby the slopeof theannual decline in FEV1 determined
from serial measurements of FEV1 obtained over a span of
years in the course of observational or intervention studies.
In intervention trials conducted over the last few decades,
this slope has been determined mainly from serial mea-
surements of the post-, rather than the pre-, bronchodilator
FEV1 [1e10]. The rationale for the latter practice appears to
derive from the assumption that theremay be less variability
in the post- than the pre-bronchodilator measurement and
that the post-bronchodilator value would be less influenced
by noncompliance with instructions to withhold bronchodi-
lator medication during the washout period prior to sched-
uled spirometric testing.However,we recently reported that
the slope estimates over 5 years, as well as the standard
errors of these estimates, were only slightly higher for the
pre- than post-bronchodilator FEV1 in 4484 LungHealth Study
(LHS) participants with mild to moderate airflow obstruction
(mean FEV1 78% predicted) [1]. These findings suggested that
serial pre-bronchodilator FEV1 measurements may be suffi-
cient for comparing the impact of interventions on the
annual rates of change in FEV1. On the other hand, the post-
bronchodilator measurements in the LHS were obtained only
approximately15 min after only 2 inhalations of a short-
acting beta-agonist, suggesting that the FEV1 response was
submaximal. Moreover, results could possibly differ in amore
severe COPD population. In order to investigate the latter
possibility, we analyzed FEV1 and FVC measured before and
30e90 min after near-maximal doses of two different bron-
chodilators at baseline and every 6 months over 4 years in a
population of patients with more advanced, moderate to
very severe COPD (mean FEV1 48% predicted) who were
participants in the Understanding Potential Long-term Im-
pacts on Function with Tiotropium (UPLIFT) trial of tio-
tropium 18 mcg Handihaler once daily vs. placebo [9].
Methods
In a post-hoc analysis using data from the UPLIFT trial, we
compared annual rates of change in pre- vs. post-bron-
chodilator FEV1 in 5041 patients with moderate to very
severe COPD (mean FEV1 48% predicted) in whom the post-
bronchodilator FEV1 was measured at the time of expected
peak action of 4 inhalations of two different classes of
short-acting inhaled bronchodilators (ipratropium, 18 mg/
inhalation, followed 1 h later by albuterol, 100 mg/inhala-
tion, followed 30 min later by spirometry) at baseline and 1
month and every 6 months post-randomization over 4
years.
Analytic methods
Annual rates of change were estimated for the two treat-
ment groups (tiotropium and placebo) separately. Among
the 5992 subjects in the original study, the 5041 (84.1%)
who had at least 3 serial measurements beginning with the
measurement at 6 months were included in this analysis.
Baseline characteristics of patients in each group aresummarized using descriptive statistics. Comparison of
distributed continuous data, the Wilcoxon rank-sum test for
non-normal continuous variables, and the Chi-square test
for categorical variables. Linear mixed effects models were
used to estimate annual change in FEV1 and FVC (ml/yr)
measured pre- and post- bronchodilator for each group
separately. The model assumed random intercept and
random slope to take into account between-subject het-
erogeneity and estimated the slope (annual decline) using
data from 6 months on (rather than from baseline) up to
year 4 to exclude the bump-up in lung function that was
observed between baseline and the 6-month visit in both
treatment groups. The analysis was also adjusted for
height, gender, smoking, baseline % predicted FEV1 (or
FVC), and baseline acute % improvement after bronchodi-
lator administration. Smoking status was categorized as
continuing smoking at all visits (n Z 629, 12.5%), sustained
ex-smoking at all visits (n Z 2972, 59.0%) and intermittent
smoking (n Z 1440, 28.6%). Separate analyses were also
performed according to GOLD grades of severity of airflow
obstruction IeII, III and IV. All analyses were performed
using SAS software v9.2 (Cary, NC).
Written informed consent was obtained from all partic-
ipants enrolled in the UPLIFT trial. The study was approved
by the institutional review boards of each of the partici-
pating centers and was conducted in accordance with the
Declaration of Helsinki and Good Clinical Practice guide-
lines. The study was registered with ClinicalTrials.gov
(number NCT00144339).Results
Of the 5992 subjects enrolled in the UPLIFT trial, 5041
(84.1%) fulfilled criteria for inclusion in the present analysis.
The baseline characteristics of these were similar to those of
the entire UPLIFT study population [9] and are shown in
Table 1. Approximately three-fourths of the participants
were male, >90% were Caucasian and their mean age was
w64 years. Average FEV1 was w40% % predicted pre- and
w48% predicted post-bronchodilator administration. Forty-
eight percent of the subjects had mild-moderate airflow
obstruction (GOLD grade IeII), 43% severe airflow obstruction
(GOLD grade III) and 8% very severe obstruction (GOLD grade
IV). Slightly less than 30% were current smokers. No differ-
ences were noted between treatment arms.
The slope estimates for the annual change in pre- and post-
bronchodilator FEV1 and FVC inml/yr obtained from the linear
mixed effects model are shown in Table 2. Slopes were
adjusted for the following covariates: height, gender, smoking
status (continuing smoking at all visits sustained, ex-smoking
at all visits and intermittent smoking), baseline FEV1 (or
FVC) % predicted, baseline % acute improvement in response
to bronchodilator administration by treatment group. The
observed data for the pre- and post-bronchodilator FEV1 and
FVC for each treatment arm are also illustrated in Fig. 1 and
Fig. 2, respectively. The adjusted slope estimates are very
similar to those unadjusted for the various covariates (Table
2). The mean slopes determined from the post- bron-
chodilator FEV1 and FVC are significantly steeper than those
calculated from the pre-bronchodilator measurements
Table 1 Baseline characteristics of subjects included in the analysis.
Study group p-value
Tiotropium Placebo
No. of subjects 2578 2463
Subject characteristics
Gender (N, % Male) 1964, 76.2% 1850, 75.1% 0.38
Age, y (Mean  SD) 64.3  8.4 64.2  8.4 0.63
Race (% White) 2323, 92.1% 2204, 91.6% 0.55
FEV1, Lepre (Mean  SD) 1.11  0.4 1.12  0.4 0.83
FEV1, % predepre (Mean  SD) 39.8  11.9 39.9  11.8 0.64
FEV1, % predepost (Mean  SD) 48.1  12.5 48.2  12.4 0.95
FVC, Lepre (Mean  SD) 2.6  0.8 2.7  0.8 0.45
FVC, Lepost (Mean  SD) 3.1  0.9 3.1  0.9 0.52
FVC, % predepre (Mean  SD) 74.8  17.9 75.4  18.0 0.23
FVC, % predepost (Mean  SD) 88.2  18.6 88.7  18.7 0.33
BMI, kg/ht2 (Mean  SD) 26.1  5.0 26.0  5.1 0.90
Smoking status (% current smokers) 745, 28.9% 722, 29.3% 0.75
Pack/years (Mean  SD) 48.9  28.0 47.9  27.9 0.17
1906 D.P. Tashkin et al.(p < 0.001), the differences being numerically larger for FVC
than FEV1 (Table 2). Although the slope differences and their
variances, in general, tend to be slightly higher in the placebo
than the tiotropium treatment arm, these between-
treatment differences are not statistically significant.
Slope estimates for the annual change in pre- and post-
bronchodilator FEV1 and FVC stratified by the severity of
airflow obstruction (GOLD grades IeII, III and IV) are shown
in Tables 3aec. For FEV1 the pre-post bronchodilator slope
differences were slightly but not significantly larger in
GOLD grades III and IV compared to GOLD grades IeII. For
FVC the pre-post bronchodilator slope differences wereTable 2 Linear slope estimates for the annual change in pre- an
and adjusted for covariates (height, gender, smoking status (see M
improvement) by intervention group. Linear mixed effects mode
Group Unadjusted
Slope estimate
ml/yr
SE ml/yr p
FEV1
Tiotropium (N Z 2578)
Pre 33.5 1.38
Post 43.9 1.41
D 10.4 1.26 <0.000
Placebo (N Z 2463)
Pre 32.6 1.40
Post 45.1 1.45
D 12.5 1.33 <0.000
FVC
Tiotropium (N Z 2578)
Pre 47.0 2.82
Post 65.0 2.81
D 18.0 2.58 <0.000
Placebo (N Z 2463)
Pre 42.1 3.04
Post 64.2 2.82
D 22.1 2.92 <0.000
a for both FEV1 and FVC, data starting from 6 months on were inclumost pronounced in GOLD grades III and IV; these differ-
ences were significantly larger in GOLD III than GOLD IeII in
the tiotropium arm (p Z 0.0011) and nearly significantly
larger in the placebo arm (p Z 0.07). They were also
significantly larger in GOLD IV than GOLD IeII in the placebo
arm (pZ 0.0055) and nearly significantly larger in GOLD IV
than GOLD IeII in the tiotropium arm (p Z 0.08).
Discussion
In this population of COPD patients with moderate to very
severe airflow limitation participating in a 4-year trial ofd post-bronchodilator FEV1 and FVC
a(ml/yr) both unadjusted
ethods), baseline % predicted FEV1 (or FVC), baseline acute %
l approach.
Adjusted
Slope estimate
ml/yr
SE ml/yr p
33.5 1.37
44.1 1.42
1 10.6 1.28 <0.0001
32.5 1.40
45.0 1.46
1 12.5 1.36 <0.0001
47.8 2.79
65.8 2.80
1 18.0 2.63 <0.0001
41.8 2.99
63.6 2.84
1 21.8 2.97 <0.0001
ded in the analysis.
Figure 1 Mean (SE) observed values of pre- and post-
bronchodilator FEV1 over 4 years in (A) the tiotropium group
and (B) the placebo group.
Figure 2 Mean (SE) observed values of pre- and post-
bronchodilator FVC over 4 years in (A) the tiotropium group
and (B) the placebo group.
Pre- vs. post-bronchodilator slopes of FEV1 change 1907tiotropium vs. placebo, unlike findings from an earlier study in
COPD patients with mild to moderate obstruction [1], the
slopes of the post-bronchodilator FEV1 and FVC are signifi-
cantly steeper than the slopes calculated from the pre-
bronchodilator measurements, while the variances are
similar, regardless of treatment arm(Table2). Thedifferences
between the pre- vs. post-bronchodilator slopes of decline in
FEV1 and FVC are numerically greater in GOLD grades III and IV
compared to GOLD grades I and II (Table 3aec).
We hypothesized that a possible reason why the slopes
determined from the post- compared to the pre-
bronchodilator measurements might be due to reduced bron-
chodilator responsiveness for both FEV1 and FVC over time.
Consequently, we examined the absolute changes (milliliters)
in FEV1 and FVC at each time point over the 4-year trial
beginningatmonth 1foreach treatment armseparately (Table
4). These data show a highly significant trend over the 4 years
of the trial toward lower absolute increments in both FEV1 and
FVC in response to bronchodilator administration in each
treatment group (p < 0.0001). This trend toward diminishing
bronchodilator responsiveness over time could provide an
explanation for the steeper post- versus pre-bronchodilator
slope since it would result in relatively lower post-
bronchodilator values in the later compared to the earlier
years of the trial, as illustrated in Fig. 3. It might also at leastpartially explain the comparatively larger differences in the
slopes of the pre- vs. post-bronchodilator measurements in
those with GOLD grades III and IV than I-II severity of airflow
obstruction (Table 3aec) since the acute bronchodilator
response (at least in terms of FEV1) tends to bemore robust in
those with moderate compared to those with severe/very
severe airflow obstruction [11,12]. This trend toward smaller
differences in the pre- vs. post-bronchodilator slopes in the
UPLIFT participants with moderate airflow obstruction
(average pre-bronchodilator FEV1 49  8 [SD] % predicted)
might also explain the absence of any discernible differences
in the pre- vs. post-bronchodilator slopes in the Lung Health
Study participants, who had only mild-to-moderate airflow
obstruction with a mean baseline FEV1 of 78% predicted [2].
Since COPD is a progressive disease characterized by an
accelerated age-related decline in lung function, the de-
gree of airflow obstruction, on average, will worsen over
time. Therefore, one explanation for the diminishing
bronchodilator response over the course of the UPLIFT trial
could be related to the impact of the progressively wors-
ening severity of airflow obstruction itself on the bron-
chodilator response. Another possible explanation could be
the development of tachyphylaxis to the acute bronchodi-
lator effect of the albuterol that was administered along
with ipratropium to elicit the post-bronchodilator FEV1 and
FVC values at each measurement point. On the other hand,
Figure 3 Estimated slopes of annual decline in pre- and post-
bronchodilator FEV1 in the tiotropium (A) and placebo (B) groups
derived from the mixed effects model with adjustment for
covariates over 4 years (solid lines) and the acute absolute in-
creases in FEV1 (in ml) from the pre-bronchodilator value
following bronchodilator administration at each time point
except for the 1-month visit (dotted vertical arrows). The
diminishing acute bronchodilator response over the 4 years of
the trial appears to account for the steeper post-bronchodilator
slope compared to the pre-bronchodilator slope.
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develops rapidly and appears to reach a plateau within
1e2 weeks of administration, after which it does not
appear to progress further [13]. Moreover, tolerance to a
beta-agonist is more evident as a decrease in the duration
of action than in the peak magnitude of bronchodilation
[14]. Since the post-bronchodilator FEV1 in the UPLIFT trial
was measured at the time of the peak response to the
combination of albuterol and ipratropium, these findings
suggest that bronchodilator tolerance does not explain the
disparity in the rates of decline between the pre- versus the
post-bronchodilator FEV1.
Whereas significant differences were noted in the pre- vs.
post-bronchodilator slopes of lung function decline, the esti-
mated variances of these slopes were similar. Therefore, no
advantage accrues to post- over pre-bronchodilator spirom-
etry with respect to reducing the variance of the slope of the
FEV1 (or FVC) in the hope of increasing statistical power todemonstrate between-treatment differences in studies
comparingdifferent interventionsonthe rateofprogressionof
COPD.While theknownwithin- andbetween-day variability of
bronchomotor tone [15] most likely contributes to the vari-
ability of the slope of FEV1 decline over time, bronchodilator
administration has not been shown to abrogate the diurnal
variability of airflow [16]. To the contrary, one might expect
even greater variability in post- compared to pre-
bronchodilator spirometry since responsiveness to broncho-
dilator administration has been shown to vary considerably
fromone session to the next [17e19]. On the other hand, prior
self-administration of a bronchodilator during the washout
period preceding spirometry test sessions in an intervention
trial would have less of an impact on post- than pre-
bronchodilator spirometric measurements.
It is of interest that post-hoc analyses of the results of the
UPLIFT trial have revealed significant between-treatment
(tiotropium vs. placebo) differences in the slope of the post-
bronchodilator (but not the pre-bronchodilator) rate of
decline in FEV1 in selected subgroups of trial participants,
namely those with moderate airflow obstruction [20],
maintenance-naı¨ve subjects [21] and younger individuals
(<50 years of age) [22]. While the reasons for the apparently
greater sensitivity of the post- compared to the pre-
bronchodilator slope of FEV1 decline in detecting differ-
ences in treatment responses in selected subgroups of COPD
patients is unclear, these findings suggest that the post-
bronchodilator slope has utility in assessing treatment ef-
fects on rates of decline in lung function.
The strengths of this study include the large number of
participants of varying severity in the UPLIFT trial, the
relatively long follow-up period of 4 years, the use of
centralized spirometry and rigorous quality control
methods that resulted in high-quality measurements of
FEV1 and FVC [23] and the use of relatively large doses of
two different classes of bronchodilators with the timing of
post-bronchodilator spirometry to correspond to the peak
magnitude of bronchodilation from each agent, so that the
post-bronchodilator measurements were likely to be near-
maximal. On the other hand, the study had important limi-
tations, particularly a high dropout rate (37% in the tio-
tropium arm andw45% in the placebo arm) that resulted in a
large amount ofmissing data.While themixed effects model
assumes that the data are missing at random, it is clear that
patient withdrawals were often due to worsening disease
leading to missing data that cannot be assumed to be at
random.Consequently, an additional analysiswas performed
in which the slope of decline in lung function was estimated
using a joint analysis approach that models the joint distri-
bution between the longitudinal outcome (FEV1 or FVC) and
the patient dropout time [24] (supplemental Table 1E); this
method reduces the estimated bias caused by premature
discontinuations. In the joint analysis, the slopes estimated
from the model adjusted for covariates are slightly higher
than those estimated from the mixed effects model, but the
differences between thepre- and post-bronchodilator slopes
determined from the two models are similar and remain
highly significant (p < 0.0001).
Another potential limitation is that somepatientsmay not
have adhered strictly to the instructions to withhold their
maintenance or rescue bronchodilator therapy for the
protocol-defined interval prior to spirometry testing. If this
Table 3a Linear slope estimates for the annual change in pre- and post-bronchodilator FEV1 and FVC
a (ml/yr) both unadjusted
and adjusted for covariates (height, gender, smoking status, baseline % predicted FEV1 (or FVC), baseline acute % improvement)
by intervention group. Linear mixed effects model approach. GOLD stage I and II.
Group Unadjusted Adjusted
Slope estimate
ml/yr
SE ml/yr p Slope estimate
ml/yr
SE ml/yr p
FEV1
Tiotropium (N Z 1227)
Pre 37.4 2.09 37.1 2.07
Post 46.1 2.14 46.2 2.13
D 8.7 1.95 <0.0001 9.1 1.98 <0.0001
Placebo (N Z 1179)
Pre 39.1 2.13 38.9 2.13
Post 50.9 2.15 50.6 2.16
D 11.8 2.03 <0.0001 11.7 2.05 <0.0001
FVC
Tiotropium (N Z 1227)
Pre 44.7 3.64 44.0 3.56
Post 53.3 3.55 52.8 3.49
D 8.6 3.48 0.0135 8.8 3.54 0.0129
Placebo (N Z 1179)
Pre 45.6 4.04 45.1 3.92
Post 60.7 3.76 60.2 3.70
D 15.1 3.97 0.0001 15.1 4.01 0.0002
a For both FEV1 and FVC, data at 6 months or later were included in the analysis.
Table 3b Linear slope estimates for the annual change in pre- and post-bronchodilator FEV1 and FVC
a (ml/yr) both unadjusted
and adjusted for covariates (height, gender, smoking status, baseline % predicted FEV1 (or FVC), baseline acute % improvement)
by intervention group. Linear mixed effects model approach. GOLD stage III.
Group Unadjusted Adjusted
Slope estimate
ml/yr
SE ml/yr p Slope estimate ml/yr SE ml/yr p
FEV1
Tiotropium (N Z 1117)
Pre 30.7 1.97 30.7 1.95
Post 42.7 2.04 42.8 2.05
D 12.0 1.74 <0.0001 12.1 1.75 <0.0001
Placebo (N Z 1060)
Pre 27.3 1.95 27.2 1.94
Post 40.5 2.12 40.3 2.12
D 13.2 1.87 <0.0001 13.1 1.89 <0.0001
FVC
Tiotropium (N Z 1117)
Pre 50.2 4.58 49.8 4.59
Post 76.7 4.68 76.3 4.69
D 26.5 4.09 <0.0001 26.5 4.12 <0.0001
Placebo (N Z 1060)
Pre 41.0 4.94 40.9 4.85
Post 67.0 4.64 66.7 4.67
D 26.0 4.64 <0.0001 25.8 4.70 <0.0001
a for both FEV1 and FVC, data at 6 months or later were included in the analysis.
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Table 3c Linear slope estimates for the annual change in pre- and post-bronchodilator FEV1 and FVC
a (ml/yr) both unadjusted
and adjusted for covariates (height, gender, smoking status, baseline % predicted FEV1 or FVC, baseline acute % improvement)
by intervention group. Linear mixed effects model approach. GOLD stage IV.
Group Unadjusted Adjusted
Slope
estimate
ml/yr
SE ml/yr p Slope estimate
ml/yr
SE ml/yr p
FEV1
Tiotropium (N Z 197)
Pre 23.7 3.56 24.2 3.64
Post 35.9 4.10 36.9 4.32
D 12.2 3.86 0.0016 12.7 3.93 0.0012
Placebo (N Z 188)
Pre 13.4 3.48 14.3 3.40
Post 28.5 3.60 28.8 3.63
D 15.1 3.80 <0.0001 14.5 3.83 0.0002
FVC
Tiotropium (N Z 197)
Pre 60.7 11.6 64.5 11.7
Post 89.7 11.2 95.7 11.7
D 29.0 11.0 0.0084 31.2 11.2 0.0053
Placebo (N Z 188)
Pre 17.7 12.6 19.8 12.8
Post 71.8 11.0 72.1 11.8
D 54.1 12.7 <0.0001 52.3 12.8 <0.0001
a for both FEV1 and FVC, data at 6 months or later were included in the analysis.
Table 4 Absolute change in milliliters (mean  SD) in FEV1
and FVC comparing post- versus pre-bronchodilator mea-
surements at each time point over 4 years.
Time FEV1 FVC
Tiotropium Placebo Tiotropium Placebo
1.0 m 197  159 235  171 347  364 486  409
0.5 y 195  159 235  168 328  336 480  398
1.0 y 183  153 231  165 319  335 470  391
1.5 y 187  157 226  165 312  334 456  392
2.0 y 184  149 219  157 314  330 448  372
2.5 y 182  150 221  159 306  327 451  389
1910 D.P. Tashkin et al.occurred, it could have affected the pre-bronchodilator
slope without influencing the slope derived from the post-
bronchodilatormeasurements; however, unless this practice
occurred systematically, it is unlikely to have affected the
difference between the pre- and post-bronchodilator slopes.
In summary, in a population of COPD patients with
moderate to very severe airflow obstruction followed for up
to 4 years as part of the UPLIFT trial of tiotropium vs.
placebo, we found significant differences in the slopes of
the rates of decline in FEV1 and FVC determined from the
post- vs. pre-bronchodilator measurements but no differ-
ences in the variances of these slopes. These pre- to post-
bronchodilator slope differences tended to be larger in
patients with severe and very severe airflow obstruction
compared to those with moderate impairment. No differ-
ences in these findings were noted between the tiotropium
and placebo treatment groups. The absolute improvements
in FEV1 and FVC after bronchodilator administration di-
minished over the 4 years of the trial, providing a potential
mechanism that might explain the steeper slopes deter-
mined from the post- compared to the pre-bronchodilator
measurements. These slope differences need to be taken
into account in studies of the impact of different in-
terventions on the rate of decline in lung function.3.0 y 175  153 214  154 290  322 430  375
3.5 y 175  147 215  156 291  319 431  384
4.0 y 166  143 206  151 278  304 408  369
p-value
for
trend
<0.0001 <0.0001 <0.0001 <0.0001Acknowledgments
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